Clinical Trial Update: Alemtuzumab + Rituximab Consolidation in CLL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating consolidation with alemtuzumab and rituximab in chronic lymphocytic leukemia has been terminated, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2011-04-29